FWM
ACAD icon

Focused Wealth Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Focused Wealth Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-400
Closed -$9K – 683
2014
Q2 		$9K Buy
+400
New +$8.35K 0.01% 433
2014
Q1 		– Sell
-1,240
Closed -$31K – 623
2013
Q4 		$31K Buy
+1,240
New +$29.3K 0.03% 220

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Focused Wealth Management's ACAD Position: Q3 2014 in Review

Focused Wealth Management sold out of Acadia Pharmaceuticals (ACAD) in Q3 2014, closing a stake of 400 shares — an estimated $9K sold.

Focused Wealth Management first reported a position in ACAD in Q4 2013 and held it in 2 quarters. The position peaked at $31K in Q4 2013. 162 funds tracked by Wall St. Rank hold ACAD as of Q3 2014.

  • Focused Wealth Management reported no remaining Acadia Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • Focused Wealth Management sold 400 Acadia Pharmaceuticals shares in Q3 2014, an estimated $9K.
  • Focused Wealth Management first reported a position in Acadia Pharmaceuticals in Q4 2013 and held it in 2 quarters.
  • Focused Wealth Management's Acadia Pharmaceuticals position peaked at $31K in Q4 2013.
  • 162 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2014.

Based on Focused Wealth Management's 13F filing for Q3 2014, filed 12 Nov 2014.